




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/10, C07C 317/10, 321/20	A1	(11) International Publication Number: WO 00/59495 (43) International Publication Date: 12 October 2000 (12.10.00)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) International Application Number: PCT/US00/08565 (22) International Filing Date: 31 March 2000 (31.03.00) (30) Priority Data: 60/127,683 2 April 1999 (02.04.99) US 60/143,975 15 July 1999 (15.07.99) US (71) Applicant (for all designated States except US): TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; Broad Street and Montgomery Avenue, Philadelphia, PA 19122 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): REDDY, E., Premkumar [US/US]; 547 Atterbury Road, Villanova, PA 19085 (US). REDDY, M., V., Ramana [IN/US]; 921 St. Joseph Drive, Upper Darby, PA 19082 (US). (74) Agent: MONACO, Daniel, A.; Seidel, Gonda, Lavorgna & Monaco, P.C., Two Penn Center Plaza, Suite 1800, Philadelphia, PA 19102 (US). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </td> </tr> </table>			(21) International Application Number: PCT/US00/08565 (22) International Filing Date: 31 March 2000 (31.03.00) (30) Priority Data: 60/127,683 2 April 1999 (02.04.99) US 60/143,975 15 July 1999 (15.07.99) US (71) Applicant (for all designated States except US): TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; Broad Street and Montgomery Avenue, Philadelphia, PA 19122 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): REDDY, E., Premkumar [US/US]; 547 Atterbury Road, Villanova, PA 19085 (US). REDDY, M., V., Ramana [IN/US]; 921 St. Joseph Drive, Upper Darby, PA 19082 (US). (74) Agent: MONACO, Daniel, A.; Seidel, Gonda, Lavorgna & Monaco, P.C., Two Penn Center Plaza, Suite 1800, Philadelphia, PA 19102 (US).	(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(21) International Application Number: PCT/US00/08565 (22) International Filing Date: 31 March 2000 (31.03.00) (30) Priority Data: 60/127,683 2 April 1999 (02.04.99) US 60/143,975 15 July 1999 (15.07.99) US (71) Applicant (for all designated States except US): TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; Broad Street and Montgomery Avenue, Philadelphia, PA 19122 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): REDDY, E., Premkumar [US/US]; 547 Atterbury Road, Villanova, PA 19085 (US). REDDY, M., V., Ramana [IN/US]; 921 St. Joseph Drive, Upper Darby, PA 19082 (US). (74) Agent: MONACO, Daniel, A.; Seidel, Gonda, Lavorgna & Monaco, P.C., Two Penn Center Plaza, Suite 1800, Philadelphia, PA 19102 (US).	(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(54) Title: (E)-STYRYL SULFONE ANTICANCER AGENTS				
(57) Abstract (E)-styryl benzylsulfones of formula (I) are useful as anticancer agents wherein R₁, R₂, R₃, and R₄ are independently selected from the group consisting of hydrogen, fluoro, chloro, iodo, bromo, C1–C6 alkyl, C1–C4 alkoxy, nitro, cyano and trifluoromethyl, with the proviso that (a) R₁, R₂, and R₃ not all hydrogen when R₄ is 2-chloro or 4-chloro; (b) when R₁ and R₃ are hydrogen and R₂ is 4-bromo or 4-chloro, then R₄ may not be 4-chloro, 4-fluoro or 4-bromo; (c) when R₁ and R₃ are hydrogen and R₂ is 4-fluoro, then R₄ may not be 4-fluoro or 4-bromo; (d) when R₁ is hydrogen, and R₄ is 2-fluoro, the R₂ and R₃ may not be 4-fluoro; and (e) when R₁ is hydrogen and R₃ is 4-hydrogen, 4-chloro, 4-bromo, 4-methyl or 4-methoxy, and R₄ is 2-hydrogen, 2-chloro, or 2-fluoro; then R₂ may not be 4-hydrogen, 4-chloro, 4-fluoro, or 4-bromo.				
 (I)				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

(E)-STYRYL SULFONE ANTICANCER AGENTS

Cross-Reference to Related Applications

The benefit of the filing date of U.S. provisional patent applications Ser. Nos. 60/127,683, filed April 2 1999, and 60/143,975 filed
5 July 15, 1999, is hereby claimed pursuant to 35 U.S.C. 119(e). The entire disclosure of the aforesaid provisional applications is incorporated herein by reference.

Field of the Invention

The invention relates to compositions and methods for the
10 treatment of cancer.

Background of the Invention

Extracellular signals received at transmembrane receptors are relayed into the cells by the signal transduction pathways (Pelech *et al.*, *Science* **257**:1335 (1992)) which have been implicated in a wide array of
15 physiological processes such as induction of cell proliferation, differentiation or apoptosis (Davis *et al.*, *J. Biol. Chem.* **268**:14553 (1993)). The Mitogen Activated Protein Kinase (MAPK) cascade is a major signaling system by which cells transduce extracellular cues into intracellular responses (Nishida *et al.*, *Trends Biochem. Sci.* **18**:128 (1993); Blumer *et al.*, *Trends Biochem. Sci.* **19**:236 (1994)). Many steps of this cascade are
20

- 2 -

conserved, and homologous for MAP kinases have been discovered in different species.

In mammalian cells, the Extracellular-Signal-Regulated Kinases (ERKs), ERK-1 and ERK-2 are the archetypal and best-studied members of the MAPK family, which all have the unique feature of being activated by phosphorylation on threonine and tyrosine residues by an upstream dual specificity kinase (Posada *et al.*, *Science* **255**:212 (1992); Biggs III *et al.*, *Proc. Natl. Acad. Sci. USA* **89**:6295 (1992); Garner *et al.*, *Genes Dev.* **6**:1280 (1992)).

Recent studies have identified an additional subgroup of MAPKs, known as c-Jun NH2-terminal kinases 1 and 2 (JNK-1 and JNK-2), that have different substrate specificities and are regulated by different stimuli (Hibi *et al.*, *Genes Dev.* **7**:2135 (1993)). JNKs are members of the class of stress-activated protein kinases (SPKs). JNKs have been shown to be activated by treatment of cells with UV radiation, pro-inflammatory cytokines and environmental stress (Derijard *et al.*, *Cell* 1025 (1994)). The activated JNK binds to the amino terminus of the c-Jun protein and increases the protein's transcriptional activity by phosphorylating it at ser63 and ser73 (Adler *et al.*, *Proc. Natl. Acad. Sci. USA* **89**:5341 (1992); Kwok *et al.*, *Nature* **370**:223 (1994)).

Analysis of the deduced primary sequence of the JNKs indicates that they are distantly related to ERKs (Davis, *Trends Biochem. Sci.* **19**:470 (1994)). Both ERKs and JNKs are phosphorylated on Tyr and Thr in response to external stimuli resulting in their activation (Davis, *Trends Biochem. Sci.* **19**:470 (1994)). The phosphorylation (Thr and Tyr) sites, which play a critical role in their activation are conserved between ERKs and JNKs (Davis, *Trends Biochem. Sci.* **19**:470 (1994)). However, these sites of phosphorylation are located within distinct dual phosphorylation motifs: Thr-Pro-Tyr (JNK) and Thr-Glu-Tyr (ERK). Phosphorylation of MAPKs and JNKs by an external signal often involves the activation of protein tyrosine kinases (PTKs) (Gille *et al.*, *Nature*

- 3 -

358:414 (1992)), which constitute a large family of proteins encompassing several growth factor receptors and other signal transducing molecules.

Protein tyrosine kinases are enzymes which catalyze a well defined chemical reaction: the phosphorylation of a tyrosine residue
5 (Hunter *et al.*, *Annu Rev Biochem* **54**:897 (1985)). Receptor tyrosine kinases in particular are attractive targets for drug design since blockers for the substrate domain of these kinases is likely to yield an effective and selective antiproliferative agent. The potential use of protein tyrosine kinase blockers as antiproliferative agents was recognized as early as
10 1981, when quercetin was suggested as a PTK blocker (Graziani *et al.*, *Eur. J. Biochem.* **135**:583-589 (1983)).

The best understood MAPK pathway involves extracellular signal-regulated kinases which constitute the Ras/Raf/MEK/ERK kinase cascade (Boudewijn *et al.*, *Trends Biochem. Sci.* **20**, 18 (1995)). Once this
15 pathway is activated by different stimuli, MAPK phosphorylates a variety of proteins including several transcription factors which translocate into the nucleus and activate gene transcription. Negative regulation of this pathway could arrest the cascade of these events.

What are needed are new anticancer chemotherapeutic
20 agents which target receptor tyrosine kinases and which arrest the Ras/Raf/MEK/ERK kinase cascade. Oncoproteins in general, and signal transducing proteins in particular, are likely to be more selective targets for chemotherapy because they represent a subclass of proteins whose activities are essential for cell proliferation, and because their activities are
25 greatly amplified in proliferative diseases.

What is also needed are new anticancer therapeutics which are highly selective in the killing of tumor cells, but not normal cells.

Summary of the Invention

30 It is an object of the invention to provide compounds, compositions and methods for the treatment of cancer and other

- 4 -


proliferative diseases. The biologically active compounds are in the form of (E)-styryl benzylsulfones.

It is an object of the invention to provide compounds which are highly selective in killing tumor cells but not normal cells.

5 It is a further object of the invention to provide novel polymers prepared by polymerization of (E)-styryl benzylsulfones.

It is a further object of the invention to provide intermediates useful for the preparation of compounds having anticancer activity. The intermediates comprise (E)-styryl benzylsulfonyl acetic acids.

10 According to one embodiment of the invention, novel compounds are provided according to formula I:



wherein:

R_1 , R_2 , R_3 , and R_4 are independently selected from the group consisting of hydrogen; fluoro; chloro; bromo; C1-C6 alkyl; C1-C6 alkoxy; 15 nitro; cyano; and trifluoromethyl;

with the proviso that

- (a) R_1 , R_2 , R_3 , and R_4 may not all be hydrogen;
- (b) when R_1 , R_2 , and R_3 are hydrogen, then R_4 may not be:
 - (i) 2- or 4-chloro or 4-fluoro;
 - (ii) 2-nitro, 3-nitro or 4-nitro;
 - (iii) 4-methoxy or 4-ethoxy; or
 - (iv) 4-methyl;
- (c) when R_1 and R_3 are hydrogen and R_2 is 4-chloro, then R_4 20 may not be 4-chloro, 4-fluoro, 4-bromo, 4-nitro, 4-isopropyl or 4-ethoxy;

- 5 -

(d) when R_1 and R_3 are hydrogen and R_2 is 4-fluoro, then R_4 may not be 4-fluoro, 4-bromo, or 4-chloro

(e) when R_1 and R_3 are hydrogen and R_2 is 4-nitro, then R_4 may not be 4-chloro, 4-nitro, 4-bromo, 4-fluoro, 4-methyl, or 4-methoxy;

5 (f) when R_1 and R_3 are hydrogen and R_2 is 4-methyl, R_4 may not be 4-chloro, 4-bromo, 4-fluoro, 4-methyl or 2-chloro;

(g) when R_1 and R_3 are hydrogen and R_2 is 4-bromo, then R_4 may not be 4-fluoro, 4-bromo or 4-chloro;

(h) when R_1 and R_2 are hydrogen, then R_3 and R_4 may not be
10 2, 4-dichloro, 2,3-dimethoxy or 3,4-dimethoxy;

(i) when R_1 is hydrogen, then R_2 , R_3 and R_4 may not all be fluoro; and

(j) when R_1 is hydrogen and R_3 is 2-fluoro, then R_2 and R_4 may not both be selected from the group consisting of 4-chloro, 4-bromo,
15 and 4-fluoro.


According to a preferred embodiment of the invention, novel compounds are provided according to formula I wherein R_1 , R_2 , R_3 , and R_4 are independently selected from the group consisting of hydrogen, chloro, fluoro, bromo, nitro, cyano and trifluoromethyl. According to a more
20 preferred embodiment, R_1 , R_2 , R_3 , and R_4 are independently selected from the group consisting of hydrogen, chloro, fluoro and bromo; most preferably hydrogen, chloro and fluoro.

In a further preferred embodiment, novel compounds are provided according to formula I wherein (1) at least one of R_1 and R_2 is
25 other than hydrogen and is located at the 2-, 3- and/or 4- position of the phenyl ring to which it is attached, and is preferably selected from chloro and fluoro, most preferably chloro; and/or (2) wherein at least one of R_3 and R_4 is other than hydrogen and is located at the 2- and/or 4- position of the phenyl ring to which it is attached, and is preferably selected from chloro
30 and fluoro. In other preferred embodiments wherein at least one of R_1 and R_2 is other than hydrogen, and at least one of R_3 and R_4 is other than

- 6 -

hydrogen, (i) R_2 is 4-halogen or 4-cyano, and R_4 is 4-nitro; or (ii) R_2 is 4-C1-C6 alkoxy, and R_4 is 4-nitro or 4-halogen. R_1 and R_3 are preferably hydrogen in these embodiments.

In another embodiment of the invention, a pharmaceutical composition is provided comprising a pharmaceutically acceptable carrier and one or more compounds of formula II:



wherein


R_1 , R_2 , R_3 , and R_4 are independently selected from the group consisting of hydrogen; fluoro; chloro; bromo; C1-C6 alkyl; C1-C6 alkoxy; nitro; cyano; and trifluoromethyl;

with the proviso that

- (a) R_1 , R_2 , and R_3 are not all hydrogen when R_4 is 2-chloro or 4-chloro;
- (b) when R_1 and R_3 are hydrogen and R_2 is 4-bromo or 4-chloro, then R_4 may not be 4-chloro, 4-fluoro or 4-bromo;
- (c) when R_1 and R_3 are hydrogen and R_2 is 4-fluoro, R_4 may not be 4-fluoro or 4-bromo;
- (d) when R_1 is hydrogen, and R_4 is 2-fluoro, then R_2 and R_3 may not be 4-fluoro;
- (e) when R_1 is hydrogen and R_3 is 4-hydrogen, 4-chloro, 4-bromo, 4-methyl or 4-methoxy, and R_4 is 2-hydrogen, 2-chloro or 2-fluoro; then R_2 may not be 4-hydrogen, 4-chloro, 4-fluoro or 4-bromo.

According to a related invention, novel compounds are provided according to formula III:

- 7 -



wherein

R_1 , R_2 , R_3 , and R_4 are independently selected from the group consisting of hydrogen; fluoro; chloro; bromo; iodo; C1-C6 alkyl; C1-C6 alkoxy; nitro; cyano; and trifluoromethyl;

5 provided at least one of R_1 , R_2 , R_3 , and R_4 is iodo.

According to a preferred embodiment, at least one of R_1 and R_2 in formula III is other than hydrogen and is located at the 2- or 4-position of the phenyl ring to which it is attached; and at least one of R_3 and R_4 is other than hydrogen and is located at the 2- or 4-position of the phenyl ring to which it is attached. According to a further preferred embodiment, R_2 and R_4 in formula III are hydrogen, and R_1 and R_3 are located at the 4-position of the respective phenyl rings to which they are attached. According to a further preferred embodiment, one of R_1 or R_3 is selected from the group consisting of chloro, fluoro, bromo and nitro, the other of R_1 or R_3 being iodo.

A pharmaceutical composition is also provided comprising a pharmaceutically acceptable carrier and one or more compounds of formula III above, wherein R_1 , R_2 , R_3 , and R_4 are defined as above for formula III.

20 Where R_1 , R_2 , R_3 or R_4 is an alkyl or alkoxy group in any compound of formulae I, II or III, the carbon chain may be branched or straight, with straight being preferred. Preferably, the alkyl and alkoxy groups comprise C1-C3 alkyl and C1-C4 alkoxy, most preferably methyl and methoxy.

- 8 -

According to another embodiment of the invention, a method of treating an individual for a proliferative disorder, particularly cancer, is provided, comprising administering to said individual an effective amount of a compound according to formula II or III, alone or in combination with
5 a pharmaceutically acceptable carrier.

In another embodiment of the invention, a method of inhibiting growth of tumor cells in an individual afflicted with cancer is provided comprising administering to said individual an effective amount of a compound according to formula II or III, alone or in combination with a
10 pharmaceutically acceptable carrier.

In another embodiment, a method of inducing apoptosis of cancer cells, more preferably tumor cells, in an individual afflicted with cancer is provided, comprising administering to said individual an effective amount of a compound according to formula II or III, alone or in
15 combination with a pharmaceutically acceptable carrier.

In yet another embodiment of the present invention, benzyl sulfones having the structural formula II or III, may be utilized as monomers in the synthesis of a new class of polymers having pendant benzylsulfone groups.

20 The present invention also provides a series of substituted benzylsulfonyl acetic acid compounds having structural formula V, below. The substituted benzylsulfonyl acetic acid compounds are useful as intermediates in the synthesis of novel (E)-styryl benzylsulfone compounds of formula I, according to Method A, below.

25

Detailed Description of the Invention

According to the present invention, certain (E)-styryl benzylsulfone derivatives selectively kill various tumor cell types without killing normal cells. Without wishing to be bound by any theory, it is believed that the compounds affect the MAPK signal transduction pathway,

thereby affecting tumor cell growth and viability. This cell growth inhibition is associated with regulation of the ERK and JNK types of MAPK. Without wishing to be bound by any theory, the styryl sulfones of the present invention may block the phosphorylating capacity of ERK-2.

5 The compounds of the invention have been shown to inhibit the proliferation of tumor cells by inducing cell death. The compounds are believed effective against a broad range of tumor types, including but not limited to the following: breast, prostate, ovarian, lung, colorectal, brain (i.e., glioma) and renal. The compounds are also believed effective against
10 leukemic cells. The compounds do not kill normal cells in concentrations at which tumor cells are killed.

 The compounds are also useful in the treatment of non-cancer proliferative disorders, including but not limited to the following: hemangiomas in new born, secondary progressive multiple sclerosis,
15 chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Paget's Disease of the bone, fibrocystic disease of the breast, Peronies and Dupuytren's fibrosis, restenosis and cirrhosis.

 Treatment of this broad range of tumor cells with the styryl
20 benzylsulfone compounds of the invention leads to inhibition of cell proliferation and induction of apoptotic cell death. In breast tumors, the effect is observed for estrogen receptor (ER) positive as well as estrogen receptor negative cells.

 Tumor cells treated with the compounds of the invention
25 accumulate in the G2/M phase of the cell cycle. As the cells exit the G2/M phase, they appear to undergo apoptosis. Treatment of normal cells with the styryl sulfones does not result in apoptosis.

Synthesis of (E)- Styryl Benzylsulfones

 The styryl benzylsulfones are characterized by cis-trans
30 isomerism resulting from the presence of one or more double bonds. The

- 10 -


compounds are named according to the Cahn-Ingold-Prelog system, the IUPAC 1974 Recommendations, Section E: Stereochemistry, in *Nomenclature of Organic Chemistry*, John Wiley & Sons, Inc., New York, NY, 4th ed., 1992, p. 127-138. Stearic relations around a double bond are
5 designated as "Z" or "E".

(E)-styryl benzylsulfones are prepared by Knoevenagel condensation of aromatic aldehydes with benzylsulfonyl acetic acids. The procedure is described by Reddy *et al.*, *Acta. Chim. Hung.* **115**:269 (1984); Reddy *et al.*, *Sulfur Letters* **13**:83 (1991); Reddy *et al.*, *Synthesis* 322
10 (1984); and Reddy *et al.*, *Sulfur Letters* **7**:43 (1987), the entire disclosures of which are incorporated herein by reference.


The (E)-styryl benzylsulfones can be prepared according to either of the following Methods A and B:

- 11 -

METHOD A



METHOD B




METHOD A

A benzyl thioacetic acid V formed by the reaction of sodium thioglycollate and a benzyl chloride IV. The benzyl thioacetic acid V is oxidized with 30% hydrogen peroxide to give a corresponding
 5 benzylsulfonyl acetic acid VI. Condensation of VI with an aromatic aldehyde VII via a Knoevenagel reaction in the presence of benzylamine and glacial acetic acid yields the (E)-styryl benzylsulfone I, II or III.

METHOD B

A benzylthioacetic acid V is formed by the reaction of the
 10 appropriate sodium benzylthiolate VIII with chloroacetic acid. Oxidation of V to the corresponding benzylsulfonyl acetic acid VI and subsequent Knoevenagel condensation with aldehyde VII is carried out as in Method A.

Substituted benzylsulfonyl acetic acid compounds Va, Vb, Vc,
 15 and Vd according to formula V were prepared by reacting the corresponding benzyl chloride with thioglycollic acid under basic conditions (Method A). These compounds are novel intermediates.




No.	Compound	R ₁	R ₂	M.P. (°C)	
20	Va	4-nitrobenzylsulfonyl acetic acid	H	4-NO ₂	165-166
	Vb	4-trifluoromethylbenzylsulfonyl acetic acid	H	4-CF ₃	164-165
	Vc	2,4-dichlorobenzylsulfonyl acetic acid	2-Cl	4-Cl	165-166
	Vd	3,4-dichlorobenzylsulfonyl acetic acid	3-Cl	4-Cl	132-134

- 13 -

(E)-Styryl benzylsulfones may be utilized as monomers in the synthesis of polymers X having pendant aryl and benzylsulfone groups. The polymerization of styryl benzylsulfones defined according to formula IX below into formula X polymers is accomplished by heating the formula IX compound above 250°C in the presence of a free radical initiator. The

5 IX compound above 250°C in the presence of a free radical initiator. The initiator may comprise benzoyl peroxide, for example:



- 14 -

The degree of polymerization in the polymer of formula X, "x", may range from about 10 to about 150, providing an oligomer or polymer of from 5,000 to 50,000 daltons. Other degrees of polymerization are also contemplated. R₁, R₂, R₃, and R₄ in the monomer of formula IX, and in the polymer of formula X, are independently selected from the group consisting of hydrogen; halogen, i.e., fluoro, chloro, bromo and iodo, most preferably fluoro, chloro and bromo; C1-C6 alkyl; C1-C6 alkoxy; nitro; cyano; and trifluoromethyl.

The (E)-styryl benzylsulfones may be derivatized with a chemical group to permit conjugation to a carrier molecule, for the purpose of raising antibodies to the styryl sulfones. Suitable derivatizing chemistries are well-known to those skilled in the art. Preferably, the derivative comprises a carboxylic acid derivative. The carrier may comprise any molecule sufficiently large to be capable of generating an immune response in an appropriate host animal. One such preferred carrier is keyhole limpet haemocyanin (KLH).

Therapeutic Administration

The (E)-styryl benzylsulfones of the invention may be administered in the form of a pharmaceutical composition, in combination with a pharmaceutically acceptable carrier. The active ingredient in such formulations may comprise from 0.1 to 99.99 weight percent. By "pharmaceutically acceptable carrier" is meant any carrier, diluent or excipient which is compatible with the other ingredients of the formulation and to deleterious to the recipient.

The compounds of the invention may be administered to individuals (mammals, including animals and humans) afflicted with cancer. The compounds are also useful in the treatment of non-cancer proliferative disorders, that is, proliferative disorders which are characterized by benign indications. Such disorders may also be known as "cytoproliferative" or "hyperproliferative" in that cells are made by the body at an atypically

- 15 -

elevated rate. Such disorders include, but are not limited to, the following: hemangiomas in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Paget's Disease of the bone, fibrocystic disease of the breast, Peronies and Dupuytren's fibrosis, restenosis and cirrhosis.

The compounds may be administered by any route, including oral and parenteral administration. Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravaginal, topical or subcutaneous administration. The active agent is preferably administered with a pharmaceutically acceptable carrier selected on the basis of the selected route of administration and standard pharmaceutical practice.

The active agent may be formulated into dosage forms according to standard practices in the field of pharmaceutical preparations. See Gennaro Alphonso, ed., *Remington's Pharmaceutical Sciences*, 18th Ed., (1990) Mack Publishing Co., Easton, PA. Suitable dosage forms may comprise, for example, tablets, capsules, solutions, parenteral solutions, troches, suppositories, or suspensions.

For parenteral administration, the active agent may be mixed with a suitable carrier or diluent such as water, an oil (particularly a vegetable oil), ethanol, saline solution, aqueous dextrose (glucose) and related sugar solutions, glycerol, or a glycol such as propylene glycol or polyethylene glycol. Solutions for parenteral administration preferably contain a water soluble salt of the active agent. Stabilizing agents, antioxidantizing agents and preservatives may also be added. Suitable antioxidantizing agents include sulfite, ascorbic acid, citric acid and its salts, and sodium EDTA. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorbutanol. The composition for parenteral administration may take the form of an aqueous or nonaqueous solution, dispersion, suspension or emulsion.

- 16 -

For oral administration, the active agent may be combined with one or more solid inactive ingredients for the preparation of tablets, capsules, pills, powders, granules or other suitable oral dosage forms. For example, the active agent may be combined with at least one excipient such as fillers, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents absorbents or lubricating agents. According to one tablet embodiment, the active agent may be combined with carboxymethylcellulose calcium, magnesium stearate, mannitol and starch, and then formed into tablets by conventional tableting methods.

The specific dose of compound according to the invention to obtain therapeutic benefit will, of course, be determined by the particular circumstances of the individual patient including, the size, weight, age and sex of the patient, the nature and stage of the disease, the aggressiveness of the disease, and the route of administration. For example, a daily dosage of from about 0.05 to about 50 mg/kg/day may be utilized. Higher or lower doses are also contemplated.

Examples

General Procedure for Synthesis (E)-Styryl Benzylsulfones

Part A. To a solution of (8g, 0.2 mol) sodium hydroxide in methanol (200 ml), thioglycollic acid (0.1 mol) is added slowly and the precipitate formed is dissolved by stirring the contents of the flask. Then an appropriately substituted or unsubstituted benzyl chloride (0.1 mol) is added stepwise and the reaction mixture is refluxed for 2-3 hours. The cooled contents are poured onto crushed ice and neutralized with dilute hydrochloric acid (200 ml). The resulting corresponding benzylthioacetic acid (0.1 mol) is subjected to oxidation with 30% hydrogen peroxide (0.12 mol) in glacial acetic acid (125 ml) by refluxing for 1 hour. The contents are

- 17 -

cooled and poured onto crushed ice. The separated solid is recrystallized from hot water to give the corresponding pure benzylsulfonylacetic acid.

Part B. A mixture of the benzylsulfonyl acetic acid (10 mmol), an appropriately substituted or unsubstituted aromatic aldehyde (10 mmol), and benzylamine (200 μ l) in glacial acetic acid (12 ml) is refluxed for 2-3 hours. The contents are cooled and treated with cold ether (50 ml). Any product precipitated out is separated by filtration. The filtrate is diluted with more ether and washed successively with a saturated solution of sodium bicarbonate (20 ml), sodium bisulfite (20 ml), dilute hydrochloric acid (20 ml) and finally with water (35 ml). Evaporation of the dried ethereal layer yields styryl benzylsulfones as a solid material.

In each of the following examples, the substituted benzylsulfonyl acetic acid was made according to Part A of the General Procedure. All the styryl benzylsulfone compounds were recrystallized from 2-propanol and the purity was checked by thin layer chromatography.

Example 1

(E)-4-Fluorostyryl-4-trifluoromethylbenzylsulfone

A solution of 4-trifluorobenzylsulfonylacetic acid (10 mmol) and 4-fluorobenzaldehyde (10mmol) was subjected to the General Procedure, Part B. The title compound melting point 166-168°C, was obtained in 82% yield.

Example 2

(E)-4-Chlorostyryl-4-trifluoromethylbenzylsulfone

A solution of 4-trifluoromethylbenzylsulfonylacetic acid (10 mmol) and 4-chlorobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 164-168°C, was obtained in 88% yield.

- 18 -

Example 3**(E)-4-Bromostyryl-4-trifluoromethylbenzylsulfone**

A solution of 4-trifluoromethylbenzylsulfonylacetic acid (10 mmol) and 4-bromobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 181-183°C, was obtained in 85% yield.

Example 4**(E)-4-Fluorostyryl-2,4-dichlorobenzylsulfone**

A solution of 2,4-dichlorobenzylsulfonyl acid (10 mmol) and 4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 146-148°C, was obtained in 78% yield.

Example 5**(E)-4-Chlorostyryl-2,4-dichlorobenzylsulfone**

A solution of 2,4-dichlorobenzylsulfonylacetic acid (10 mmol) and 4-chlorobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 148-149°C, was obtained in 84% yield.

Example 6**(E)-4-Fluorostyryl-3,4-dichlorobenzylsulfone**

A solution of 3,4-dichlorobenzylsulfonylacetic acid (10 mmol) and 4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 120-122°C, was obtained in 82% yield.

Example 7**(E)-4-Chlorostyryl-3,4-dichlorobenzylsulfone**

5 A solution of 3,4-dichlorobenzylsulfonylacetic acid (10 mmol) and 4-chlorobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 149-151°C, was obtained in 86% yield.

Example 8**(E)-4-Bromostyryl-3,4-dichlorobenzylsulfone**

10 A solution of 3,4-dichlorobenzylsulfonylacetic acid (10 mmol) and 4-bromobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 154-155°C, was obtained in 84% yield.

Example 9**(E)-4-Fluorostyryl-4-nitrobenzylsulfone**

15 A solution of 4-nitrobenzylsulfonylacetic acid (10 mmol) and 4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 160-161°C, was obtained in 76% yield.

Example 10**20 (E)-4-Fluorostyryl-4-cyanobenzylsulfone**

A solution of 4-cyanobenzylsulfonylacetic acid (10 mmol) and 4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure Part B. The title compound, melting point 150-151°C, was obtained in 82% yield.

Example 11**(E)-4-Chlorostyryl-4-cyanobenzylsulfone**

A solution of 4-cyanobenzylsulfonyl acetic acid (10 mmol) and 4-chlorobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 173-177°C, was obtained in 86% yield.

Example 12**(E)-4-Bromostyryl-4-cyanobenzylsulfone**

A solution of 4-cyanobenzylsulfonyl acetic acid (10 mmol) and 4-bromobenzaldehyde (10 mmol) was subjected to the General Procedure, Part B. The title compound, melting point 183-184°C, was obtained in 77% yield.

Example 13**(E)-3,4-Difluorostyryl-4-chlorobenzylsulfone**

A solution of 4-chlorobenzylsulfonyl acetic acid (10 mmol) and 3,4 difluorobenzaldehyde was subjected to the General Procedure, Part B. The title compound, melting point 204-205°C, was obtained in 73% yield.

Example 14**(E)-3-Chloro-4-fluorostyryl-4-chlorobenzylsulfone**

A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 3-chloro-4-fluorobenzaldehyde was subjected to the General Procedure, Part B. The title compound, melting point 181-183°C, was obtained in 78% yield.

Example 15**(E)-2-Chloro-4-fluorostyryl-4-chlorobenzylsulfone**

A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2-chloro-4-fluorobenzaldehyde was subjected to the General Procedure,

Part B. The title compound, melting point 149-150°C, was obtained in 68% yield.

Example 16

(E)-2,4-Dichlorostyryl-4-chlorobenzylsulfone

5 A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2,4-dichlorobenzaldehyde was subjected to the General Procedure, Part B. The title compound, melting point 164-165°C, was obtained in 78% yield.

Example 17

(E)-3,4-Dichlorostyryl-4-chlorobenzylsulfone

10 A solution of 4-chlorobenzylsulfonyl acetic acid (10 mmol) and 3,4-dichlorobenzaldehyde (10 mmol) was subjected to the General procedure, Part B. The title compound, melting point 170-171°C, was obtained in 73% yield.

Example 18

(E)-2,3-Dichlorostyryl-4-chlorobenzylsulfone

15 A solution of 4-chlorobenzylsulfonyl acetic acid (10 mmol) and 2,3-dichlorobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 170-171°C, was obtained in 72% yield.

20 Example 19

(E)-4-Fluorostyryl-4-iodobenzylsulfone

25 A solution of 4-iodobenzylsulfonyl acetic acid (10 mmol) and 4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 171-173°C, was obtained in 98% yield. (¹HNMR, CDCl₃) δ 4.27(s, CH₂), 6.60 (d, = CH, J = 15.7 Hz), 7.18-7.80 (m, 9H, Aro + = CH).

Example 20**(E)-4-Iodostyryl-4-fluorobenzylsulfone**

A solution of 4-fluorobenzylsulfonyl acetic acid (10 mmol) and 4-iodobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 168-170°C, was obtained in 58% yield.

Example 21**(E)-4-Iodostyryl-4-chlorobenzylsulfone**

A solution of 4-chlorobenzylsulfonyl acetic acid (10 mmol) and 4-iodobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 181-182°C, was obtained in 70% yield. (1HNMR, CDCl₃) δ 4.27(s, CH₂), 6.60 (d, = CH, J = 15.7 Hz), 7.18-7.80 (m, 9H, Aro + = CH).

Example 22**(E)-4-Iodostyryl-4-bromobenzylsulfone**

A solution of 4-bromobenzylsulfonyl acetic acid (10 mmol) and 4-iodobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 201-203°C, was obtained in 71% yield.

Example 23**(E)-4-Chlorostyryl-4-iodobenzylsulfone**

A solution of 4-iodobenzylsulfonyl acetic acid (10 mmol) and 4-chlorobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 200-202°C, was obtained in 86% yield. (1HNMR, CDCl₃) δ 4.27(s, CH₂), 6.60 (d, = CH, J = 15.7 Hz), 7.18-7.80 (m, 9H, Aro + = CH).

Example 24**(E)-4-Bromostyryl-4-iodobenzylsulfone**

A solution of 4-iodobenzylsulfonyl acetic acid (10 mmol) and 4-bromobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 217-219°C, was obtained in 88% yield.

Example 25**(E)-2-Nitrostyryl-4-iodobenzylsulfone**

A solution of 4-iodobenzylsulfonyl acetic acid (10 mmol) and 2-nitrobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 227-229°C, was obtained in 62% yield.

Example 26**(E)-4-Nitrostyryl-4-iodobenzylsulfone**

A solution of 4-iodobenzylsulfonyl acetic acid (10 mmol) and 4-nitrobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 227-228°C, was obtained in 62% yield.

Example 27**(E)-4-Iodostyryl-4-methoxybenzylsulfone**

A solution of 4-methoxybenzylsulfonyl acetic acid (10 mmol) and 4-iodobenzaldehyde (10 mmol) was subjected to the General Procedure, part B. The title compound, melting point 201-203°C, was obtained in 56% yield.

Example 28**(E)-4-Iodostyryl-2,4-dichlorobenzylsulfone**

A solution of 2,4-dichlorobenzylsulfonyl acetic acid (10 mmol) and 4-iodobenzaldehyde (10 mmol) was subjected to the General Procedure, part

B. The title compound, melting point 181-182°C, was obtained in 60% yield.

The following additional compounds In Table 1 were prepared according to the same synthetic methods (M.P. = melting point):

5

Table 1

10

15

20

25

Ex.	M.P. (°C)	Yield (%)	Compound
29	134-136	55	(E)-2-nitrostyryl-4-fluorobenzylsulfone
30	170-173	64	(E)-3-nitrostyryl-4-fluorobenzylsulfone
31	151-152	61	(E)-4-nitrostyryl-4-fluorobenzylsulfone
32	96-98	54	(E)-2-trifluoromethylstyryl-4-fluorobenzylsulfone
33	117-119	55	(E)-3-trifluoromethylstyryl-4-fluorobenzylsulfone
34	125-128	73	(E)-4-trifluoromethylstyryl-4-fluorobenzylsulfone
35	108-112	52	(E)-2-trifluoromethy-4-fluorostyryl-4-fluorobenzylsulfone
36	128-132	58	(E)-2-nitrostyryl-4-chlorobenzylsulfone
37	156-157	60	(E)-3-nitrostyryl-4-chlorobenzylsulfone
38	189-191	61	(E)-4-nitrostyryl-4-chlorobenzylsulfone
39	100-101	55	(E)-2-trifluoromethylstyryl-4-chlorobenzylsulfone
40	155-157	58	(E)-3-trifluoromethylstyryl-4-chlorobenzylsulfone
41	164-166	59	(E)-4-trifluoromethylstyryl-4-chlorobenzylsulfone
42	115-117	63	(E)-2-trifluoromethyl-4-fluorostyryl-4-chlorobenzylsulfone
43	169-171	63	(E)-3-methyl-4-fluorostyryl-4-chlorobenzylsulfone
44	136-138	57	(E)-2-nitrostyryl-2,4-dichlorobenzylsulfone
45	136-138	57	(E)-2-trifluoromethyl-4-fluorostyryl-2,4-dichlorobenzylsulfone
46	131-132	63	(E)-2-nitrostyryl-4-bromobenzylsulfone
47	168-170	56	(E)-3-nitrostyryl-4-bromobenzylsulfone
48	205-207	67	(E)-4-nitrostyryl-4-bromobenzylsulfone
49	102-104	57	(E)-2-trifluoromethylstyryl-4-bromobenzylsulfone
50	160-161	55	(E)-3-trifluoromethylstyryl-4-fluorobenzylsulfone

- 25 -

5	51	174-175	62	(E)-4-trifluoromethylstyryl-4-bromoyanobenzylsulfone
	52	167-168	63	(E)-2-nitrostyryl-4-cyanobenzylsulfone
	53	192-193	62	(E)-3-nitrostyryl-4-cyanobenzylsulfone
	54	219-220	66	(E)-4-nitrostyryl-4-cyanobenzylsulfone
	55	182-184	70	(E)-4-fluorostyryl-4-methylbenzylsulfone
10	56	191-192	70	(E)-4-bromostyryl-4-methylbenzylsulfone
	57	128-130	51	(E)-2-nitrostyryl-4-methylbenzylsulfone
	58	201-203	56	(E)-3-nitrostyryl-4-methylbenzylsulfone
	59	194-195	57	(E)-4-nitrostyryl-4-methylbenzylsulfone
	60	148-149	60	(E)-4-fluorostyryl- 4-methoxybenzylsulfone
15	61	176-177	66	(E)-4-chlorostyryl-4-methoxybenzylsulfone
	62	179-181	60	(E)-4-bromostyryl-4-methoxybenzylsulfone
	63	127-129	57	(E)-2-nitrostyryl-4-methoxybenzylsulfone
	64	153-155	59	(E)-3-nitrostyryl-4-methoxybenzylsulfone
	65	179-181	56	(E)-4-nitrostyryl-4-methoxybenzylsulfone
	66	176-177	66	(E)-4-chlorostyryl-4-nitrobenzylsulfone
	67	199-200	60	(E)-4-fluorostyryl-4-nitrobenzylsulfone

Effect of (E)-Styryl Benzylsulfones on Breast, and Prostate Tumor Cell Lines

20 A. Cells.

The effect of the (E)-styryl benzylsulfones on normal fibroblasts and on tumor cells of breast, and prostate origin was examined utilizing one or more of the following cell lines: breast tumor cell lines MCF-7 and BT-20; prostate tumor cell line DU-145; colorectal carcinoma cell line DLD-1; non-
25 small cell lung carcinoma cell line H157; and NIH/3T3 and HFL cells. MCF-7 is estrogen-responsive, while BT-20 is an estrogen-unresponsive cell line. NIH/3T3 and HFL are normal murine and human fibroblasts, respectively. MCF-7, BT-20, DLD-1 and H157 were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum supplemented
30 with penicillin and streptomycin. DU145 was cultured in RPMI with 10%

- 26 -

fetal bovine serum containing penicillin and streptomycin. NIH3T3 and HFL cells were grown in DMEM containing 10% calf serum supplemented with penicillin and streptomycin. All cell cultures were maintained at 37°C in a humidified atmosphere of 5% CO₂.


5 B. Treatment with (E)-Styryl Sulfones and Viability Assay

Cells were treated with test compound at 2.5 mM concentration and cell viability was determined after 96 hours by the Trypan blue exclusion method. The results are set forth in Table 2. Activity for each compound is reported as a range of cell induced death (% Death) with the lowest
10 activity in the range of 5-10% and the highest being above 80%.

Normal cells HFL and NIH 3T3 were treated with the same compounds in Table 2 under the same conditions of concentration and time. The normal cells displayed 5% growth inhibition but no appreciable cell death.

- 27 -

Table 2
Effect of (E)-styryl benzylsulfones on tumor cells



	Ex	R ₁	R ₂	R ₃	R ₄	Tumor cell type			H157	BT20
						MCF-7	DU145	DLD-1		
5	1	4-CF ₃	H	4-F	H	+++	+++	+++	++	+++
	2	4-CF ₃	H	4-Cl	H	++	++	++	ND	++
	3	4-CF ₃	H	4-Br	H	ND	+	+	ND	++
	4	2-Cl	4-Cl	4-F	H	++	++	ND	+	++
	5	2-Cl	4-Cl	4-Cl	H	+++	+	++	++	ND
10	6	3-Cl	4-Cl	4-F	H	++++	++++	ND	ND	++++
	7	3-Cl	4-Cl	4-Cl	H	ND	-	ND	ND	++
	8	3-Cl	4-Cl	4-Br	H	ND	-	-	ND	-
	9	4-NO ₂	H	4-F	H	++	++	-	++	++
	10	4-CN	H	4-F	H	+++	++	ND	+++	ND
15	11	4-CN	H	4-Cl	H	+	+	ND	+	ND
	12	4-CN	H	4-Br	H	-	-	-	+	ND
	13	4-Cl	H	3-F	4-F	-	-	-	-	ND
	14	4-Cl	H	3-Cl	4-F	-	-	-	-	ND
	15	4-Cl	H	2-Cl	4-F	+++++	+++++	+++++	+++++	ND
20	16	4-Cl	H	2-Cl	4-Cl	++++	+++	++++	ND	ND
	17	4-Cl	H	3-Cl	4-Cl	+	+	+	ND	ND
	18	4-Cl	H	2-Cl	3-Cl	+	+	+	ND	ND
	19	4-I	H	4-F	H	ND	+++++	+++++	+++++	+++++
	20	4-F	H	4-I	H	ND	ND	ND	ND	ND
25	21	4-Cl	H	4-I	H	ND	++	++	++	++
	22	4-Br	H	4-I	H	ND	++	++	++	++

- 28 -

5	23	4-I	H	4-Cl	H	ND	++	++	++	+++
	24	4-I	H	4-Br	H	ND	ND	ND	ND	ND
	25	4-I	H	2-NO ₂	H	ND	++	++	++	++
	26	4-I	H	4-NO ₂	H	ND	ND	ND	ND	ND
	27	4-CH ₃ O	H	4-I	H	ND	ND	ND	ND	ND
10	28	4-Cl	2-Cl	4-I	H	ND	ND	ND	ND	ND
	29	4-F	H	2-NO ₂	H	ND	+	+	+	+
	30	4-F	H	3-NO ₂	H	ND	+	+	+	+
	31	4-F	H	4-NO ₂	H	ND	++++	++++	++++	++++
	32	4-F	H	2-CF ₃	H	ND	+	+	+	+
15	33	4-F	H	3-CF ₃	H	ND	+	+	+	+
	34	4-F	H	4-CF ₃	H	ND	+	+	+	+
	35	4-F	H	2-CF ₃	4-F	ND	+	+	+	+
	36	4-Cl	H	2-NO ₂	H	ND	+	+	+	+
	37	4-Cl	H	3-NO ₂	H	ND	+	+	+	+
20	38	4-Cl	H	4-NO ₂	H	ND	++++	++++	++++	++++
	39	4-Cl	H	2-CF ₃	H	ND	+	+	+	+
	40	4-Cl	H	3-CF ₃	H	ND	+	+	+	+
	41	4-Cl	H	4-CF ₃	H	ND	+	+	+	+
	42	4-Cl	H	4-F	2-CF ₃	ND	+	+	+	+
25	43	4-Cl	H	4-F	3-CH ₃	ND	+	+	+	+
	44	4-Cl	2-Cl	4-NO ₂	H	ND	+	+	+	+
	45	4-Cl	2-Cl	4-F	2-CF ₃	ND	+++	+++	+++	+++
	46	4-Br	H	2-NO ₂	H	ND	+	+	+	+
	47	4-Br	H	3-NO ₂	H	ND	+	+	+	+
30	48	4-Br	H	4-NO ₂	H	ND	++++	++++	++++	++++
	49	4-Br	H	2-CF ₃	H	ND	+	+	+	+
	50	4-Br	H	3-CF ₃	H	ND	+	+	+	+
	51	4-Br	H	4-CF ₃	H	ND	+	+	+	+
	52	4-CN	H	2-NO ₂	H	ND	+	+	+	+
	53	4-CN	H	3-NO ₂	H	ND	+	+	+	+
	54	4-CN	H	4-NO ₂	H	ND	++++	++++	++++	++++
	55	4-CH ₃	H	4-F	H	ND	+	+	+	+
	56	4-CH ₃	H	4-Br	H	ND	+	+	+	+

- 29 -

5	57	4-CH ₃	H	2-NO ₂	H	ND	+	+	+	+
	58	4-CH ₃	H	3-NO ₂	H	ND	+	+	+	+
	59	4-CH ₃	H	4-NO ₂	H	ND	+	+	+	+
	60	4-CH ₃ O	H	4-F	H	ND	+++++	+++++	+++++	+++++
	61	4-CH ₃ O	H	4-Cl	H	ND	++++	++++	++++	++++
10	62	4-CH ₃ O	H	4-Br	H	ND	++++	++++	++++	++++
	63	4-CH ₃ O	H	2-NO ₂	H	ND	+	+	+	+
	64	4-CH ₃ O	H	3-NO ₂	H	ND	+	+	+	+
	65	4-CH ₃ O	H	4-NO ₂	H	ND	++++	++++	++++	++++
	66	4-NO ₂	H	4-Cl	H	ND	+	+	+	+
	67	4-NO ₂	H	4-F	H	ND	+	+	+	+

Cell death:

15	0%	=	-	50-60%	=	++++
	5-10%	=	+	Above 80%	=	+++++
	10-15%	=	++	ND	=	not done
	40-50%	=	+++			

Example 68**Conjugation of (E)-4-Fluorostyryl 4-chlorobenzylsulfone to Keyhole Limpet Haemocyanin**

20 A carboxylic acid derivative of (E)-4-fluorostyryl 4-chlorobenzylsulfone was synthesized by mixing 4-chlorobenzyl sulfonyl acetic acid (10 mmol), 4-fluorobenzaldehyde (10mmol), glacial acetic acid (15 ml) and piperidine (0.5 ml) at room temperature (22°C) over a magnetic stirrer for 5 hours. The mixture was then diluted with ether and the ethereal

25 layer was washed with water. Evaporation of the ethereal layer yielded a semisolid material which on treating with 2-propanol gave a white solid. Recrystallization with 2-propanol gave 2-(4-chlorobenzyl sulfonyl)-3-(4-fluorophenyl) propenoic acid as white crystals, (yield 32%), m.p 111-112°C.

30 The above carboxylic acid derivative (10 mM) was made into an active ester by treatment with 10 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 10 mM N-hydroxysuccinamide (NHS), and then cross-linked to KLH by mixing with 1

- 30 -


ml of a KLH water solution containing 500 mg KLH. The mixture was stirred at room temperature for 5-6 hours. The KLH conjugate was then separated by passing the mixture through a size exclusion column (PD 10, Pharmacia). The conjugate was then used to inject rabbits for raising
5 antibodies.

All references cited with respect to synthetic, preparative and analytical procedures are incorporated herein by reference.

The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and,
10 accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indication the scope of the invention.

CLAIMS

1. A compound of the formula:



wherein:

- 5 R_1 , R_2 , R_3 , and R_4 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano and trifluoromethyl

with the proviso that

- (a) R_1 , R_2 , R_3 , and R_4 may not all be hydrogen;
- 10 (b) when R_1 , R_2 , and R_3 are hydrogen, then R_4 may not be:
- (i) 2- or 4-chloro or 4-fluoro;
- (ii) 2-nitro, 3-nitro or 4-nitro;
- (iii) 4-methoxy or 4-ethoxy; or
- (iv) 4-methyl;
- 15 (c) when R_1 and R_3 are hydrogen and R_2 is 4-chloro, then R_4 may not be 4-chloro, 4-fluoro, 4-bromo, 4-nitro, 4-isopropyl or 4-ethoxy;
- (d) when R_1 and R_3 are hydrogen and R_2 is 4-fluoro, then R_4 may not be 4-fluoro, 4-bromo, or 4-chloro;
- (e) when R_1 and R_3 are hydrogen and R_2 is 4-nitro, then R_4 may not
- 20 be 4-chloro, 4-nitro, 4-bromo, 4-fluoro, 4-methyl or 4-methoxy;
- (f) when R_1 and R_3 are hydrogen and R_2 is 4-methyl, then R_4 may not be 4-chloro, 4-bromo, 4-fluoro, 4-methyl or 2-chloro;
- (g) when R_1 and R_3 are hydrogen and R_2 is 4-bromo, R_2 then may not be 4-fluoro, 4-bromo or 4-chloro;

- 32 -

(h) when R_1 and R_2 are hydrogen, then R_3 and R_4 may not be 2, 4-dichloro, 2,3-dimethoxy or 3,4-dimethoxy;

(i) when R_1 is hydrogen, then R_2 , R_3 and R_4 may not all be fluoro; and

(j) when R_1 is hydrogen and R_3 is 2-fluoro, then R_2 and R_4 may not
5 both be selected from the group consisting of 4-chloro, 4-bromo, and 4-fluoro.

2. A compound according to claim 1 wherein at least one of R_1 and R_2 is other than hydrogen and is located at the 2-, 3- or 4- position of the phenyl ring to which it is attached; and wherein at least one of R_3 and
10 R_4 is other than hydrogen and is located at the 2- or 4-position of the phenyl ring to which it is attached.

3. A compound according to claim 2 wherein the compound is (E)-4-fluorostyryl-4-trifluoromethylbenzylsulfone.

4. A compound according to claim 2 wherein the compound is
15 (E)-2-trifluoromethyl-4-fluorostyryl-2,4-dichlorobenzylsulfone.

5. A compound according to claim 2 wherein the compound is (E)-4-fluorostyryl-4-cyanobenzylsulfone.

6. A compound according to claim 2 wherein at least one of R_1 and R_2 is chloro and at least one of R_3 and R_4 is chloro or fluoro.

20 7. A compound according to claim 6 wherein the compound is (E)-4-fluorostyryl-3,4-dichlorobenzylsulfone.

8. A compound according to claim 6 wherein the compound is (E)-4-fluorostyryl-2,4-dichlorobenzylsulfone.

- 33 -

9. A compound according to claim 6 wherein the compound is (E)-2-chloro-4-fluorostyryl-4-chlorobenzylsulfone.
10. A compound according to claim 6 wherein the compound is (E)-2,4-dichloro-4-chlorobenzylsulfone.
- 5 11. A compound according to claim 11 wherein the compound is (E)-4-fluorostyryl-4-nitrobenzylsulfone.
12. A compound according to claim 2 wherein R_2 is 4-halogen or 4-cyano, and R_4 is 4-nitro.
- 10 13. A compound according to claim 11 wherein the compound is (E)-4-nitrostyryl-4-fluorobenzylsulfone.
14. A compound according to claim 11 wherein the compound is (E)-4-nitrostyryl-4-bromobenzylsulfone.
15. A compound according to claim 11 wherein the compound is (E)-4-nitrostyryl-4-cyanobenzylsulfone.
- 15 16. A compound according to claim 2 wherein R_2 is 4-C1-C6 alkoxy, and R_4 is 4-halogen or 4-nitro.
17. A compound according to claim 16 wherein the compound is (E)-4-fluorostyryl-4-methoxybenzylsulfone.
18. A compound according to claim 16 wherein the compound is (E)-4-chlorostyryl-4-methoxybenzylsulfone
- 20 19. A compound according to claim 16 wherein the compound is


- 34 -

(E)-4-bromostyryl-4-methoxybenzylsulfone.

20. A compound according to claim 16 wherein the compound is (E)-4-nitrostyryl-4-methoxybenzylsulfone.

21. A compound of the formula:

5



wherein:

R_1 , R_2 , R_3 , and R_4 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano and trifluoromethyl,

10 provided at least one of R_1 , R_2 , R_3 or R_4 is iodo.

22. A compound according to claim 21 wherein at least one of R_1 and R_2 is other than hydrogen and is located at the 2- or 4- position of the phenyl ring to which it is attached; and wherein at least one of R_3 and R_4 is other than hydrogen and is located at the 2- or 4-position of the phenyl ring to which it is attached.

15

23. A compound according to claim 22 wherein R_2 and R_4 are hydrogen, and R_1 and R_3 are located at the 4-position of the phenyl rings to which they are attached.

24. A compound according to claim 23 wherein one of R_2 or R_4 is selected from the group consisting of chloro, fluoro, bromo and nitro.


20

- 35 -

25. A compound according to claim 24 selected from the group consisting of (E)-4-iodostyryl-4-fluorobenzylsulfone, (E)-4-iodostyryl-4-chlorobenzylsulfone, (E)-4-iodostyryl-4-bromobenzylsulfone and (E)-4-chlorostyryl-4-iodobenzylsulfone.

5 26. A compound according to claim 24 which is (E)-4-fluorostyryl-4-iodobenzylsulfone.

27. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:



wherein

10 R₁, R₂, R₃, and R₄ are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano and trifluoromethyl,

with the proviso that

- 15 (a) R₁, R₂, and R₃ not all hydrogen when R₄ is 2-chloro or 4-chloro;
 (b) when R₁ and R₃ are hydrogen and R₂ is 4-bromo or 4-chloro, then R₄ may not be 4-chloro, 4-fluoro or 4-bromo;
 (c) when R₁ and R₃ are hydrogen and R₂ is 4-fluoro, then R₄ may not be 4-fluoro or 4-bromo;
 (d) when R₁ is hydrogen, and R₄ is 2-fluoro, the R₂ and R₃ may not
 20 be 4-fluoro; and
 (e) when R₁ is hydrogen and R₃ is 4-hydrogen, 4-chloro, 4-bromo, 4-methyl or 4-methoxy, and R₄ is 2-hydrogen, 2-chloro, or 2-fluoro; then R₂ may not be 4-hydrogen, 4-chloro, 4-fluoro, or 4-bromo.

28. A composition according to claim 27 wherein the compound is selected from the group consisting of (E)-4-fluorostyryl-4-trifluorobenzylsulfone, (E)-2-trifluoromethyl-4-fluorostyryl-2,4-dichlorobenzylsulfone, (E)-4-fluorostyryl-4-cyanobenzylsulfone, (E)-4-fluorostyryl-3,4-dichlorobenzylsulfone, (E)-4-fluorostyryl-2,4-dichlorobenzylsulfone, (E)-2-chloro-4-fluorostyryl-4-chlorobenzylsulfone, and (E)-4-fluorostyryl-4-nitrobenzylsulfone, (E)-4-chlorostyryl-4-nitrobenzylsulfone, (E)-4-nitrostyryl-4-fluorobenzylsulfone, (E)-4-nitrostyryl-4-bromobenzylsulfone, (E)-4-nitrostyryl-4-cyanobenzylsulfone, (E)-2,4-dichloro-4-chlorobenzylsulfone, (E)-4-fluorostyryl-4-methoxybenzylsulfone, (E)-4-chlorostyryl-4-methoxybenzylsulfone, (E)-4-bromostyryl-4-methoxybenzylsulfone, and (E)-4-nitrostyryl-4-methoxybenzylsulfone.

29. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 21.

30. A method of treating an individual for a proliferative disorder comprising administering to said individual an effective amount of a pharmaceutical composition according to claim 21 or 29.

31. A method according to claim 30 wherein the proliferative disorder is selected from the group consisting of hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.

32. A method according to claim 30 wherein the proliferative disorder is cancer.


- 37 -

33. A method of according to claim 32 wherein the cancer is selected from the group consisting of ovarian, breast, prostate, lung, renal, colorectal and brain cancers, or the cancer is a leukemia.

34. A method of inducing apoptosis of tumor cells in an individual afflicted with cancer comprising administering to said individual an effective amount of a pharmaceutical composition according to claim 21 or 29.

35. A method according to claim 34 wherein the tumor cells are selected from the group consisting of ovarian, breast, prostate, lung, colorectal, renal and brain tumors.

36. A compound useful as an intermediate in the synthesis of a compound according to claim 1, said intermediate compound having the formula



wherein:


R₁ and R₂ are both halogen; or
R₁ is hydrogen and R₂ is nitro or CF₃;
or a salt thereof.

37. A compound according to claim 36 wherein R₁ and R₂ are both chloro.

38. A compound according to claim 37 selected from the group consisting of 4-nitrobenzyl sulfonyl acetic acid, 4-trifluorobenzylsulfonyl acetic acid, 2,4-dichlorobenzylsulfonyl acetic acid and 3,4-dichlorobenzylsulfonyl acetic acid, and salts thereof.

- 38 -

39. A process for producing a polymer of the formula:




wherein:

x is from about 10 to about 150; and

R_1 , R_2 , R_3 , and R_4 are independently selected from the group
 5 consisting of hydrogen, fluoro, chloro, iodo, bromo, C1-C6 alkyl, C1-C6
 alkoxy, nitro, cyano and trifluoromethyl;

comprising heating a compound of the formula:



- 39 -

above 250°C in the presence of a free radical initiator, wherein R₁, R₂, R₃, and R₄ in the compound are independently selected from the group consisting of hydrogen, fluoro, chloro, iodo, bromo, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano and trifluoromethyl.

- 5 40. A process according to claim 39 wherein R₁, R₂, R₃, and R₄ are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano and trifluoromethyl.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/08565**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 31/10; C07C 317/10; 321/20

US CL : 514/709; 562/429; 568/28, 30, 32, 34, 35, 36, 39

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/709; 562/429; 568/28, 30, 32, 34, 35, 36, 39

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database Caplus on STN, Chemical abstracts (Columbus Ohio, USA), CA:127:33922, EVANS, P. 'The epoxy-Ramberg-Baecklund reaction: a new route to allylic alcohols' abst of Tetrathedron Lett. 38(17) pp 3055-3058, 1997.	1-29
A	Database Caplus on STN, Chemical abstracts (Columbus Ohio, USA), CA; 110:74956, REDDY, D.B. 'Preparation of styryl benzyl sulfones and 1,2-bis(styrylsulfonylmethyl)-4, 5-dimethylbenzenes', abst of Org. Prep. Proced. Int. 30(3) pp 205-12, 1988.	1-29

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 JUNE 2000

Date of mailing of the international search report

22 SEP 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized Officer
JEAN F. VOLLANO

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/08565

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database Caplus on STN, Chemical abstracts (Columbus Ohio, USA), CA:101:23063, REDDY, M.V.R. 'Synthesis of alpha beta-unsaturated sulfones' abst of Acta Chim. Hung. 115 (3) pp 269-271, March 1984.	1
X	Database Caplus on STN, Chemical abstracts (Columbus Ohio, USA), CA:125:327911, RIAD, Y. 'Kinetics and mechanism of the catalytic reduction of [[(4-nitrophenyl)-methyl]sulfonyl] acetic acid in alkaline dioxane-water media', abst of Egypt. J. Chem., 39 (4), pp 353-364, 1996.	36, 38
X	Database Caplus on STN, Chemical abstracts (Columbus Ohio, USA), CA:120:210378 CHENG, H.M. 'Metabolism of ¹⁴ C-ring-labeled benthocarb in mice and rats' abst of J. Chin. Biochem. Soc. 22(1) pp 27-35, 1993.	36
X	Database Caplus on STN, Chemical abstracts (Columbus Ohio, USA), CA:103:141088, JANCZEWSKI, M. 'Effect of molecular structure on optical properties of sulfoxide systems. m-Bromobenzylsulfinylacetic acids and some of their derivatives' abst of Pol. J. Chem. 58(1-2-3) pp 103-16, 1984	36
X ---- A	US 3,463,774 A (W. WENNER et al) 26 August 1969 (26/8/69) see entire document, especially examples.	36 ---- 37-38
A	Database Caplus on STN, Chemical abstracts (Columbus Ohio, USA), CA:121:256180, LI, C. 'Synthesis and pharmacological evaluation of vinyl sulfone based anticancer agents' abst of Bioorg. Med. Chem. Lett. 4(13), pp 1595-90, 1994	27-32

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/08565

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-29, 30-31(in part) and claims 36-38.
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☒

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/08565

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

CAS ONLINE, BEILSTEIN, EAST

search terms: structure drawings, sulfones and cancer, hemangiomatosis

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

i

1. This International Search Authority has found 16 inventions claimed in the International Application covered by the claims indicated below:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-26, drawn to compounds of the formula of instant claim 1.

Group II, claim(s) 27-29, drawn to pharmaceutical compositions which contain a composition including compounds broader in scope than compounds in Group I.

Group III, claim(s) 30, 32 (in part), drawn to a method of treating cancer.

Group IV, claim(s) 30-31 (in part), drawn to a method of treating multiple sclerosis.

Group V, claim(s) 30, 32 (in part), drawn to a method of treating hemangiomatosis.

Group VI, claim(s) 30-31 (in part), drawn to a method of treating myelodegenerative disease.

Group VII, claim(s) 30, 32 (in part), drawn to a method of treating neurofibromatosis.

Group VIII, claim(s) 30-31 (in part), drawn to a method of treating ganglioneuromatosis.

Group IX, claim(s) 30, 32 (in part), drawn to a method of treating keloid formation .

Group X, claim(s) 30-31 (in part), drawn to a method of treating Pagets Disease of the bone.

Group XI, claim(s) 30-31 (in part), drawn to a method of treating fibrocystic disease of the breast.

Group XII, claim(s) 30, 32 (in part), drawn to a method of treating Peronies and Duputen's fibrosis.

Group XIII, claim(s) 30-31 (in part), drawn to a method of treating restenosis.

Group XIV, claim(s) 30, 32 (in part), drawn to a method of treating cirrhosis .

Group XV, claim(s) 36-38, drawn to a carboxylic acid of the formula found in claim 36.

Group XVI, claim(s) 39-40, drawn to a method for producing a polymer using a racemic mixture or unspecified isomers.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2, and 13.3) for reasons listed below:

The inventions listed as Groups I-XVI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The compounds being claimed in Group I are E isomers of certain compounds including known compounds as taught in CA:128:48012. The pharmaceutical compositions of Group II contain compounds which are not found in Group I such as the compound wherein al the R groups are hydrogen, as taught in CA:114:5934. Thus the scope of the pharmaceutical composition is broader than the compounds being claimed. There is no special technical feature which links the compound and the compositions being claimed since the scope is broader and since compounds of Group II are known. Groups III-XIV are all drawn to the method of using the pharmaceutical compositions of Group II. However, under unity of invention there is a unity of invention the compound/composition and a method of use. There are more than one method of use and if Applicant chooses Group II, then Applicant is asked to choose one method of use under unity of invention that will be examined as one group. Groups III-XIV are various methods of use which are independent of each other. Group XV is drawn to a carboxylic acid compound. This is related as an intermediate. However since the compounds of Group I are known then there is no special technical feature which links Group I and Group XV. The compound of Group I can be prepared similarly to the process found in CA:128:48012. It is also noted that there is no intermediate-final product grouping under unity of invention. Group II is a composition and not related to Group XV under unity of invention. Group XVI is a process for forming a polymer which uses compounds not found in Group I. Group XVI is not related by a special technical feature to a pharmaceutical composition nor is it linked to the method of treatment in Groups III-XIV.